Herein, we confirmed this hypothesis showing that both genetic and pharmacological inhibition of C5a/C5aR1 signaling, especially in neutrophils, had a beneficial effect on a preclinical mouse model of COVID-19. The gene discussed is C5; the disease is COVID-19.